JP2018537415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537415A5 JP2018537415A5 JP2018519031A JP2018519031A JP2018537415A5 JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5 JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- multivalent
- terminus
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15189665.1A EP3156417A1 (en) | 2015-10-13 | 2015-10-13 | Multivalent fv antibodies |
| EP15189665.1 | 2015-10-13 | ||
| PCT/EP2016/074642 WO2017064221A1 (en) | 2015-10-13 | 2016-10-13 | Multivalent fv antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537415A JP2018537415A (ja) | 2018-12-20 |
| JP2018537415A5 true JP2018537415A5 (cg-RX-API-DMAC7.html) | 2019-11-21 |
| JP6936497B2 JP6936497B2 (ja) | 2021-09-15 |
Family
ID=54325413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519031A Active JP6936497B2 (ja) | 2015-10-13 | 2016-10-13 | 多価Ｆｖ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11572415B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3156417A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6936497B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180057720A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108473577A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016336866B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018007445A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001765A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258638B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018004547A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201803083XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017064221A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201802543B (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6839101B2 (ja) | 2015-06-15 | 2021-03-03 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ヘテロ二量体多重特異性抗体フォーマット |
| CN117946278A (zh) * | 2017-06-25 | 2024-04-30 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| WO2019175368A1 (en) | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| CN111527108A (zh) * | 2018-03-27 | 2020-08-11 | 西雅图免疫公司 | 制导和导航控制蛋白的制造和使用方法 |
| US20240132626A1 (en) * | 2018-04-13 | 2024-04-25 | Eli Lilly And Company | Fab-Based Trispecific Antibodies |
| MX2020010728A (es) * | 2018-04-13 | 2020-11-06 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk. |
| AU2019255270A1 (en) * | 2018-04-17 | 2020-11-19 | Invenra Inc. | Trivalent trispecific antibody constructs |
| PL3843757T3 (pl) | 2018-08-27 | 2024-08-05 | Affimed Gmbh | Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała |
| EP4034245A1 (en) * | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Trivalent binding molecules |
| CN118599006A (zh) * | 2019-11-06 | 2024-09-06 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| JP2023545099A (ja) | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| CA3203468A1 (en) * | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| WO2022174813A1 (zh) * | 2021-02-19 | 2022-08-25 | 信达生物制药(苏州)有限公司 | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| AU2022356387A1 (en) * | 2021-09-29 | 2024-04-18 | Modex Therapeutics, Inc. | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof |
| CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
| US20230272069A1 (en) * | 2022-02-28 | 2023-08-31 | Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences | Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025235413A1 (en) * | 2024-05-05 | 2025-11-13 | Duke University | Compositions targeting cancer antigens and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| AU705484B2 (en) * | 1994-01-07 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| EP1294904A1 (en) * | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| PL372144A1 (en) * | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CN101517075A (zh) * | 2006-07-13 | 2009-08-26 | 中外制药株式会社 | 细胞死亡诱导剂 |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| EP2655415A4 (en) | 2010-12-22 | 2016-03-09 | Abbvie Inc | THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| PT2925782T (pt) * | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
| JP2016510319A (ja) | 2012-12-28 | 2016-04-07 | アッヴィ・インコーポレイテッド | 多価結合タンパク質組成物 |
| WO2014201378A1 (en) * | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| JP6839101B2 (ja) * | 2015-06-15 | 2021-03-03 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ヘテロ二量体多重特異性抗体フォーマット |
-
2015
- 2015-10-13 EP EP15189665.1A patent/EP3156417A1/en not_active Withdrawn
-
2016
- 2016-10-13 CN CN201680073236.5A patent/CN108473577A/zh active Pending
- 2016-10-13 IL IL258638A patent/IL258638B2/en unknown
- 2016-10-13 BR BR112018007445A patent/BR112018007445A2/pt not_active Application Discontinuation
- 2016-10-13 WO PCT/EP2016/074642 patent/WO2017064221A1/en not_active Ceased
- 2016-10-13 AU AU2016336866A patent/AU2016336866B2/en not_active Ceased
- 2016-10-13 EP EP16791328.4A patent/EP3362478A1/en not_active Withdrawn
- 2016-10-13 MX MX2018004547A patent/MX2018004547A/es unknown
- 2016-10-13 SG SG11201803083XA patent/SG11201803083XA/en unknown
- 2016-10-13 CA CA3001765A patent/CA3001765A1/en active Pending
- 2016-10-13 KR KR1020187013310A patent/KR20180057720A/ko not_active Ceased
- 2016-10-13 JP JP2018519031A patent/JP6936497B2/ja active Active
- 2016-10-13 SG SG10202004094VA patent/SG10202004094VA/en unknown
-
2018
- 2018-04-11 US US15/950,733 patent/US11572415B2/en active Active
- 2018-04-17 ZA ZA2018/02543A patent/ZA201802543B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537415A5 (cg-RX-API-DMAC7.html) | ||
| JP2017176174A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536322A5 (cg-RX-API-DMAC7.html) | ||
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| JP2017504578A5 (cg-RX-API-DMAC7.html) | ||
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2014158485A5 (cg-RX-API-DMAC7.html) | ||
| JP2017529067A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533239A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513476A5 (cg-RX-API-DMAC7.html) | ||
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| JP2020517287A5 (cg-RX-API-DMAC7.html) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| HRP20171608T1 (hr) | Protutijela koja vežu albumin i njihovi vezujući fragmenti | |
| JP2016531924A5 (cg-RX-API-DMAC7.html) | ||
| AR076797A1 (es) | Anticuerpos triespecificos o tetraespecificos | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| JP2016538240A5 (cg-RX-API-DMAC7.html) | ||
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| JP2019502694A5 (cg-RX-API-DMAC7.html) |